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sue antigen expression, evaluation and cutoff determina-
tion, single potentially useful prognostic markers could be 
identified.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 The normal cell cycle is characterized by the complex 
interactions of cyclins, cyclin-dependent kinases and 
their inhibitors  [1] . Though the cell cycle regulation is not 
fully understood, the prognostic value of cell cycle-regu-
lating proteins in malignant tumors has been widely 
studied and reported to be of significance in urothelial 
carcinoma (UC) of the bladder  [1–7] . Among the most 
promising prognostic markers concerning survival, re-
currences and progression are those involved in the G1/S-
phase transition, such as cyclin D1 (CCND1) and E 
(CCNE), and cyclin-dependent kinase inhibitors, such as 
p27, p16 and p21, as well as p53  [1, 8] . Molecular studies 
revealed loss of chromosome 9 in up to 50% of UCs and 
p16 located at 9p21 was identified as a major target gene 
in early bladder cancer  [9] . Expression of cell cycle mark-
ers has been linked to grade, stage and survival, but indi-
vidual markers so far have not proved to be superior to 
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 Abstract 
 Aims: We investigated the value of multiple cell cycle mark-
ers for their prognostic impact on overall survival and recur-
rence-free survival in urothelial carcinoma (UC).  Methods: A 
tissue microarray consisting of 99 UCs was evaluated for the 
expression of p53, p16, p21, p27, cyclin D1, cyclin E , Bcl-2, Ki-
67 and PCNA. Statistical analysis was performed applying 
Kaplan-Meier and Cox regression models using receiver op-
erator characteristic curves for determination of markers’ 
cutoffs.  Results: Expression above the cutoffs of Ki-67, p53 
and p27, particularly in high-grade and early-stage UC, was 
associated with worse overall survival, while expression of 
p16 indicated a better outcome in low-grade and low-stage 
tumors. Recurrence-free survival was better in patients with 
high-grade UC expressing PCNA, p16 and cyclin E, and low-
grade UC expressing Bcl-2 above the cutoffs, but worse in all 
tumors with high Ki-67.  Conclusion: Cell cycle deregulation 
in UC is complex and the prognostic value of the various in-
volved proteins should be differentially regarded with re-
spect to this complexity and other tumor characteristics 
such as grade and stage. Our results point towards the role 
of p16- and p27-associated pathways in tumor progression 
 Received: June 15, 2007 
 Accepted after revision: October 16, 2007 
 Dr. Andrea Brunner 
 Institute of Pathology, Medical University of Innsbruck 
 Muellerstrasse 44 
 AT–6020 Innsbruck (Austria) 
 Tel. +43 512 9003 71306, Fax +43 512 582 088, E-Mail andrea.brunner@i-med.ac.at 
 © 2008 S. Karger AG, Basel
1015–2008/08/0751–0025$24.50/0 
 Accessible online at:
www.karger.com/pat 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:3
3:
47
 P
M
 Brunner /Verdorfer /Prelog /Mayerl /
Mikuz /Tzankov 
Pathobiology 2008;75:25–3326
classical prognostic parameters  [10–13] . Studies on com-
binations of different markers that might enhance the 
predictive power, including p53 together with p16, 
CCND1 and CCNE together with phosphorylated retino-
blastoma protein as well as p21 and p27, suggest multiple 
alterations, especially in invasive UC that might contrib-
ute to recurrence, progression and, finally, worse surviv-
al  [3–5, 14] . The expression of the antiapoptotic protein 
Bcl-2 and the proliferation index, assessed by Ki-67 and 
PCNA, have been reported to be potentially useful in pre-
dicting prognosis as well  [4, 5, 7, 12, 14–17] . Nevertheless, 
results obtained in different studies remain controver-
sial.
 To further assess the prognostic value of these multi-
ple markers in UC and rationally address determination 
of prognostic cutoff levels applying receiver operator 
characteristics (ROC)-based methods, a large-scale im-
munohistochemical study on 99 specimens of patients 
with UC of the bladder in a tissue microarray (TMA) for-
mat was performed.
 Material and Methods 
 Samples 
 Ninety-nine primary diagnoses of UC of the bladder, obtained 
by means of transurethral resection and diagnosed between Jan-
uary 1994 and December 1997 at the Institute of Pathology, Med-
ical University of Innsbruck, were included in our study. All cas-
es were reviewed by 2 pathologists (A.B. and G.M.) and reclassi-
fied according to the WHO 2004 classification. Our study group 
consisted of 27 pTa (22 low-grade and 5 high-grade UCs), 33 pT1 
(2 low-grade and 32 high-grade UCs), 34 pT2–4 tumors (all high-
grade UCs) and 5 carcinomata in situ (CIS). The clinical and path-
ological characteristics of the 99 patients have been reported else-
where  [18] .
 TMA Construction 
 Samples were brought into a TMA format as previously de-
scribed  [19] . Three tissue cores (0.6 mm) and, in small specimens, 
1–3 cores were obtained based on tissue amount including super-
ficial, invasive portion tumor and the adjacent stroma.
 Immunohistochemistry 
 Immunohistochemistry was performed, except for CCNE and 
p21, which were manually incubated, on an automated immuno-
stainer (Nexes; Ventana), applying the streptavidin-biotin perox-
idase technique with diaminobenzidine as chromogen. The anti-
bodies, sources, dilutions, pretreatment and staining patterns are 
summarized in  table 1 . Immunohistochemical staining was eval-
uated calculating the mean value of the relative proportion (per-
centage) of positively staining cells of the individual cores of each 
case based on at least 100 cells/case. For p16 and p27 cytoplasmic 
staining was also considered as previously reported  [20, 21] .
 Statistics 
 The Statistical Package of Social Sciences (SPSS 12.0 for Win-
dows) was used. The Spearman rank test was used to test correla-
tions between individual markers. The analysis of variance 
(ANOVA) was used to compare means between groups. For de-
Table 1. Antibodies, sources, dilutions, pretreatment and staining patterns
Antibody Source Clone Dilution Pretreatment Staining pattern
Ki-67 Dako MIB-1 1:100 wet autoclave;
citrate buffer (pH 6)
nuclear
PCNA Dako PC10 1:300 microwave (10 min, 750W);
distilled water
nuclear
p53 Dako DO-7 1:50 wet autoclave;
citrate buffer (pH 6)
nuclear
p21 Neomarkers HZ52 1:400 microwave;
citrate buffer (pH 6)
nuclear
p27 Dako SX53G8 1:100 wet autoclave;
citrate buffer (pH 6)
nuclear/cytoplasmic
p16 Neomarkers 16PO4
(JC2)
1:50 wet autoclave;
citrate buffer (pH 6)
nuclear/cytoplasmic
CCND1 Vector/Al SP4 1:100 wet autoclave;
citrate buffer (pH 6)
nuclear
CCNE Neomarkers 13A3 1:20 microwave;
citrate buffer (pH 6)
nuclear
Bcl-2 Dako 124 1:50 wet autoclave;
citrate buffer (pH 6)1
cytoplasmic
1 Amplifier A/B (Ventana).
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termination of optimal cutoff values of continuous variables, 
ROC curves by plotting sensitivity versus 1 – specificity were 
used. The optimal cutoff point was calculated using Youden’s in-
dex (Y)  [22] . Overall survival (OS) and recurrence-free survival 
(RFS) were analyzed by the Kaplan-Meier method applying the 
cutoff values calculated by ROC/Y and compared by the log rank 
test, except for continuous variables, where a Cox regression mod-
el was applied. Multivariate analysis was performed to identify 
independent prognostic markers for OS and RFS using a Cox mul-
tistep regression model. p  ! 0.05 was considered significant.
 Results 
 TMA Quality 
 Three tissue cores/case could be arrayed in 90 cases, 
whereas 2 and 1 core could be obtained in 6 and 3 cases, 
respectively, resulting in a total number of 285 cores. Af-
ter immunohistochemistry, between 225 (79%) and 262 
(92%) cores and between 89 (90%) and 94 (95%) cases 
could be evaluated.
 Expression and Correlations 
 The number of evaluable cases, the number of positive 
cases and the mean percentage  8 SD of positively stain-
ing cells, as well as the cutoffs for OS and RFS are sum-
marized in  table 2 . Nuclear and cytoplasmic expression 
of p16 was found in all positively staining specimens, 
while p27 expression was mainly restricted to the nuclei 
with only 6 specimens exhibiting additional cytoplasmic 
staining (fig. 1). The correlations between markers are 
shown in  table 3 . Compared with clinical and pathologi-
cal parameters, such as age, grade, stage, recurrence and 
Table 2. Number of evaluable cases (n), number of positive cases 
(np), mean expression and cutoff values for OS and RFS deter-
mined by ROC of the studied markers
n np1 Mean 
expression2
Cutoff 
OS, %
Cutoff 
RFS, %
Ki-67 93 91 (98) 26.75820.81 9.5 8.75
PCNA 89 88 (99) 58.60831.82 58 74
p53 93 43 (46) 20.16831.47 14 4.5
p21 92 91 (99) 93.14819.46 98 98
p27 90 46 (46) 8.82816.42 5.5 4.5
p16 93 42 (45) 18.22830.29 1.5 23
CCND1 89 35 (39) 8.07817.20 0.15 7
CCNE 94 66 (70) 18.94823.07 8.5 0.2
Bcl-2 91 52 (57) 14.12819.70 13.15 1.55
1 Figures in parentheses are percentages.
2 Data are presented as mean percentages 8 SD.
Table 3. Correlations between different markers
Ki-67
PCNA 0.342
0.001
0.217
0.044
p53 0.445
0.000
0.288
0.006
p21 0.210
0.047
p16 0.320
0.002
0.301
0.004
–0.241
0.024
CCNE 0.292
0.005
0.262
0.012
0.433
0.000
0.311
0.003
–0.235
0.028
0.278
0.007
Bcl-2 0.231
0.028
0.284
0.007
Ki-67 p53 p21 p27 CCND1 p16
Calculated by Spearman rank test. The upper figures are cor-
relation coefficients, the lower italicized figures are p values.
Table 4. ROC and Kaplan-Meier analysis for markers showing 
prognostic significance concerning OS and RFS
ROC Kaplan-Meier analysis
AUROC p value cutoff, % median OS plog rank
Ki-67 0.571 0.287 >9.5 30 0.004*
<9.5 118
p53 0.536 0.593 >14 17 0.047*
<14 62
p27 0.564 0.351 >5.5 31 0.03*
<5.5 57
p16 0.584 0.213 >1.5 64 0.087
<1.5 35
CCND1 0.663 0.021* >0.15 64 0.065
<0.15 31
median RFS plog rank
Ki-67 0.516 0.793 >8.5 10 0.018*
<8.5 88
PCNA 0.599 0.11 >74 90 0.023*
<74 12
p16 0.587 0.154 >23 80 0.027*
<23 12
CCNE 0.603 0.09 >0.2 71 0.014*
<0.2 9
Bcl-2 0.60 0.106 >1.55 71 0.003*
<1.55 38
AUROC = Area under ROC curve. * p < 0.05.
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disease progression, only Ki-67, PCNA and p53 were as-
sociated with higher grade (p ANOVA  ! 0.001, p ANOVA = 
0.001 and p ANOVA = 0.001, respectively) and stage (p ANOVA 
 ! 0.001, p ANOVA = 0.021 and p ANOVA  ! 0.001, respectively). 
Ki-67 and CCND1 expression were higher in tumors 
with  subsequent disease progression (p ANOVA = 0.042 and 
p ANOVA = 0.032, respectively). High CCNE expression 
correlated with the presence of tumor-associated CIS 
(p ANOVA = 0.018).
 Receiver Operator Characteristics 
 ROC showed significant discriminatory power con-
sidering OS for the expression of CCND1, with an opti-
mal cutoff value of 0.15% ( table 4 ). For all other markers, 
ROC curves showed only borderline significance or 
lacked discriminatory power considering OS ( table 4 ). 
ROC showed borderline discriminatory significance for 
RFS for PCNA, CCNE, Bcl-2, p16 and p27, but lacked sig-
nificant discriminatory power for all other markers ( ta-
ble 4 ). Cutoff values for all markers considering OS and 
RFS determined by ROC/Y and used for Kaplan-Meier 
analysis are shown in  table 2 .
 Overall Survival 
 OS was influenced by age, grade, stage and number of 
recurrences, but not by tumor-associated CIS and pro-
gressive disease  [18] . A worse OS was found for Ki-67, p53 
and p27 expression above the cutoff ( table 4 ;  fig. 2 a).
a
c d
b
 Fig. 1. High-grade bladder cancer with nuclear and cytoplasmic expression of p16 ( a ,  b ;  ! 200 and  ! 400); low-
grade bladder cancer with nuclear p27 expression and slight cytoplasmic staining ( c ;  ! 400) as well as strong 
nuclear expression of CCNE in a high-grade tumor ( d ;  ! 200). 
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 Stratified by grade, p27 and Ki-67 expression above 
the cutoff, but not p53, were associated with a worse OS 
in high-grade tumors (p log rank = 0.028 and p log rank = 
0.036, respectively). Stratified by stage, this finding held 
true for p27 expression in pTa and pT1 tumors (p log rank = 
0.039 and p log rank = 0.014, respectively;  fig. 2 b–d). In ad-
dition, p16 expression in  1 1.5% of tumor cells showed an 
association with a better OS in low-grade (mean OS 103 
months, median survival was not reached) and pTa tu-
mors (mean OS 109 months, median survival was not 
reached) compared to p16 expression in  ! 1.5% of tumor 
cells (mean OS 63 months, median OS 72 months and 
mean OS 73 months, median OS 84 months, respectively; 
p = 0.043 and p = 0.019, respectively;  fig. 3 a, b).
 Multivariate analysis for OS considering age, grade, 
stage, number of recurrences, Ki-67, p53, p27 and p16 re-
vealed that only increased age (relative risk = 1.062, 95% 
CI 1.108–1.018, p = 0.005), low number of recurrences 
(relative risk = 0.682, 95% CI 0.499–0.933, p = 0.017) and 
p53 expression in  1 14% (relative risk = 1.026, 95% CI 
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 Fig. 2.  a Expression of p27 above the cutoff is associated with a worse OS in UC of the bladder. Stratified by 
grade and stage, p27 expression above the cutoff indicates a worse OS in high-grade ( b ) as well as in pTa ( c ) and 
pT1 ( d ) tumors. p27  ! 5.5% versus p27  1 5.5% compared by the log rank test. n = Number of events/number of 
cases. 
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1.008–1.044, p = 0.004) were independent predictors of a 
worse OS.
 Recurrence-Free Survival 
 Ki-67 expression in  1 8.75% of tumor cells was associ-
ated with a shorter RFS when compared to tumors with 
Ki-67 expression in  ! 8.75%. Patients with PCNA expres-
sion of more than 74% had a longer RFS than those with 
PCNA expression below 74%. Similarly, Bcl-2, CCNE and 
p16 expression above the cutoff was associated with a bet-
ter RFS ( table 4 ). Considering all other known clinical 
and morphological parameters, only progress at relapse 
was associated with a worse RFS  [18] .
 Stratified by grade and stage, PCNA expression above 
the cutoff was associated with a longer RFS only in high-
grade tumors (p log rank = 0.023). CCNE expression above 
the cutoff was only associated with a better RFS in high-
grade (p log rank = 0.02), pTa (p log rank = 0.043) and pT1 
tumors (p log rank = 0.008). Expression of p16 above the 
cutoff predicted a longer RFS in high-grade (p log rank = 
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 Fig. 3. Expression of p16 above the cutoff is significantly associated with a better OS in low-grade ( a ) and pTa 
( b ) tumors and predicts a better RFS in high-grade ( c ) and pT2–4 tumors ( d ). p16  ! 1.5% versus p16  1 1.5% and 
p16  ! 23% versus p16  1 23% compared by the log rank test. n = Number of events/number of cases. 
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0.011) and pT2–4 tumors (p log rank = 0.024;  fig. 3 c, d). 
Bcl-2 expression above the cutoff was a predictor for a 
better RFS  in  low-grade  (p log rank  =  0.0005)  and  pTa   tu-
mors   (p log rank = 0.0001). Ki-67 did not show any asso-
ciation with RFS when either stratified for grade or 
stage.
 Multivariate analysis for RFS considering progressive 
disease, Ki-67, PCNA, CCNE, p16 and Bcl-2 showed that 
only lacking progressive disease (relative risk = 0.234, 
95% CI 0.109–0.503, p  ! 0.001), Bcl-2 (relative risk = 
0.978, 95% CI 0.958–0.998, p = 0.032) and CCNE expres-
sion (relative risk = 0.983, 95% CI 0.966–0.999, p = 0.04) 
were independent prognostic factors considering better 
RFS.
 Discussion 
 In UC a variety of studies have investigated cell cycle 
markers for their predictive value concerning disease-
free, overall and disease-specific survival, but results of-
ten remained contradictory  [2, 10] . Possible reasons in-
clude the heterogeneity of evaluated cases in different 
studies. Another important point is the use of different 
cutoffs for marker positivity, with only few studies deter-
mining the optimal cutoff values by ROC, rather than by 
stepwise analysis or by median or mean percentages of 
positively staining cells  [6, 7, 12] . Similarly to previous 
studies, increased expression of Ki-67 and p53 proved to 
be associated with a worse OS in our collective  [4, 12, 
15–17] . Indeed, p53 mutations have been suggested as a 
key event in the development of aggressive UC phenotype 
 [23] .
 A particular new aspect of our study concerns the 
prognostic value of p16 and p27 protein expression. p16 
was assessed as nuclear and cytoplasmic staining, as pre-
viously reported, though some authors regard cytoplas-
mic staining for p16 as nonspecific  [20] . Nuclear expres-
sion of p16 above the cutoff values was associated with a 
better OS in low-grade and low-stage tumors and pre-
dicted a better RFS in high-grade and high-stage tumors 
in our patient cohort. Hitchings et al.  [20] and Korkolo-
poulou et al.  [24] , who studied the influence of p16 on 
disease survival and progression, emphasized the protec-
tive effect of p16 in UC, especially in tumors without p53 
accumulation and normal expression of p16, which is in 
accordance with our finding of improved OS in low-
grade and pTa tumors, believed to lack p53 mutations 
 [23] . Indeed, p16 promotor hypermethylations resulting 
in inactivation are more frequently observed in invasive 
than noninvasive tumors, indicating that inactivation of 
p16 is associated with a more aggressive phenotype, but 
the reported hypermethylation frequencies in UC of the 
bladder vary considerably  [9, 25] . Additionally, lost p16 
expression could also be due to deletions at 9p21, which 
are commonly observed in UC, but such deletions are as 
frequent or even more frequent in pTa and low-grade tu-
mors compared to high-grade tumors  [9, 26, 27] . Thus, 
retained p16 expression in UC, as observed in our cohort, 
may identify a distinct subgroup of both low- and high-
grade as well as low- and high-stage UC patients without 
 p16 gene alterations, which are probably accompanied by 
a better prognosis. Strong cytoplasmic p16 staining was 
often seen in high-grade tumors (all with accompanying 
nuclear staining), pointing towards a probable deregula-
tion leading to cytoplasmic retention of p16, analogously 
to p27  [21] . Nevertheless, in our study RFS was better in 
these patients as well and one may speculate that cyto-
plasmic p16 accumulation could simply reflect a compen-
satory mechanism to overcome other defects in cell cycle 
regulation. We observed a negative correlation between 
p16 and CCND1 expression. Loss of p16 and high CCND1 
has been shown to be associated with hyperphosphory-
lated retinoblastoma protein, resulting in increased cell 
proliferation  [8] . Intact p16 could probably counterbal-
ance the oncogenic potential of CCND1 in UC  [2, 4, 8] . 
Interestingly in that consideration, we observed a tenden-
cy towards better OS for patients with CCND1 expression 
and several authors have linked CCND1 expression to 
low grade, low stage and better OS, too  [2, 5] . It seems 
likely that the proposed oncogenic role of CCND1 can be 
modified, particularly in UC, by alterations in other cell 
cycle-controlling molecules, such as loss of p16 or p53 
mutations. Such complex interactions may probably be 
responsible for the observed association of CCND1 
 expression with subsequent UC progression despite its 
 potential positive prognostic importance considering OS 
 [4, 6] .
 Loss of p27 in bladder cancer has been reported to 
 indicate a worse prognosis in UC  [28] . In contrast, we 
showed that p27 expression in  1 5.5% of tumor cells is as-
sociated with worse OS in high-grade and pTa/pT1 tu-
mors. Expression of p27 has been reported to be associ-
ated with an adverse disease outcome in diffuse large B 
cell lymphomas and posttranslational modifications 
were found to be responsible for the loss of the growth-
inhibitory function of p27 despite its cellular accumula-
tion  [21, 29] . Increased p27 expression in superficial high-
grade tumors may probably represent accumulation of a 
nonfunctional protein, which is supported by the pres-
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